ResMed (RMD)

• Market cap: $39.8B
• 1 day: -0.33%
• 5 days: 0.14%
• 1 month: -5.04%
• 3 months: 8.64%
• 6 months: 20.9%
• Year to date: 18.92%
• 1 year: 8.3%
• 5 years: 57.16%
• 10 years: 430.17%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 10,600

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

66% more first-time investments, than exits

New positions opened: 121 | Existing positions closed: 73

14% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 8 (+1) [Q2]

14% more capital invested

Capital invested by funds: $20.8B [Q1] → $23.7B (+$2.89B) [Q2]

4% more funds holding

Funds holding: 871 [Q1] → 906 (+35) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 349 | Existing positions reduced: 319

0.7% less ownership

Funds ownership: 63.44% [Q1] → 62.74% (-0.7%) [Q2]

44% less call options, than puts

Call options by funds: $109M | Put options by funds: $196M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $270
• Avg. target: $292
• High target: $325

6 analyst ratings

• positive: 4 67%
• neutral: 2 33%
• negative: 0 0%

Mizuho Anthony Petrone	$290	Outperform Maintained	1 Aug 2025
Stifel Jonathan Block	$270	Hold Maintained	1 Aug 2025
RBC Capital Craig Wong-Pan	$300	Outperform Maintained	1 Aug 2025
UBS Laura Sutcliffe	$325	Buy Maintained	1 Aug 2025
Keybanc Brett Fishbin	$298	Overweight Maintained	1 Aug 2025